| 臺大學術典藏 |
2020-05-25T02:45:22Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Lee J.-H;Chen H.-Y;Feng-Ming Hsu;Chen J.-S;Liao W.-Y;Shih J.-Y;Yu C.-J;Chen K.-Y;Tsai T.-H;Yang J.C.-H.; Lee J.-H; Chen H.-Y; Feng-Ming Hsu; Chen J.-S; Liao W.-Y; Shih J.-Y; Yu C.-J; Chen K.-Y; Tsai T.-H; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T01:33:01Z |
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
|
YEN-TING LIN; Wang Y.-F.; Yang J.C.-H.; Yu C.-J.; Wu S.-G.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-05-25T01:33:00Z |
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non–Small-Cell Lung Cancer: Analysis and Literature Review
|
YEN-TING LIN; Yu C.-J.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-25T01:32:59Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
|
YEN-TING LIN; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-25T01:32:58Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-20T05:11:45Z |
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
|
Wu S.-G.; Shih J.-Y.; Yang P.-C.; Yu C.-J.; Yang J.C.-H.; Wang Y.-F.; YEN-TING LIN; Yang P.-C.;Shih J.-Y.;Wu S.-G.;Yu C.-J.;Yang J.C.-H.;Wang Y.-F.;YEN-TING LIN |
| 臺大學術典藏 |
2020-05-20T05:11:44Z |
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non�VSmall-Cell Lung Cancer: Analysis and Literature Review
|
Yang J.C.-H.; Yu C.-J.; YEN-TING LIN; Shih J.-Y.;Yang J.C.-H.;Yu C.-J.;YEN-TING LIN; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:43Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non�VSmall-cell Lung Cancer
|
Shih J.-Y.;Yang J.C.-H.;Wu S.-G.;Liu Y.-N.;YEN-TING LIN; YEN-TING LIN; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:42Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.;Yang J.C.-H.;Shih J.-Y.;Lin Z.-Z.;Lee J.-H.;Chen K.-Y.;Yang C.-Y.;Hsu C.-L.;Ho C.-C.;Liao W.-Y.;Chen J.-S.;YEN-TING LIN; YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
Cheng A.-L.; Twelves C.; Bogenrieder T.; Huang D.C.-L.; Strelkowa N.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Shiah H.-S.; Yang J.C.-H.; CHIH-HUNG HSU; Lee J.-H.; de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; De Bono J.;Lin C.-C.;Chen L.-T.;Corral J.;Michalarea V.;Rihawi K.;Ong M.;Lee J.-H.;Chih-Hung Hsu;Yang J.C.-H.;Shiah H.-S.;Yen C.-J.;Anthoney A.;Jove M.;Buschke S.;Fuertig R.;Schmid U.;Goeldner R.-G.;Strelkowa N.;Huang D.C.-L.;Bogenrieder T.;Twelves C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:08Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Lee J.-H.;Chen T.W.-W.;Chih-Hung Hsu;Yen Y.-H.;Yang J.C.-H.;Cheng A.-L.;Sasaki S.-I.;Chiu L.Y.;Sugihara M.;Ishizuka T.;Oguma T.;Tajima N.;Lin C.-C.; Chen T.W.-W.; CHIH-HUNG HSU; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2020-04-27T08:45:08Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.;Xiao F.;Shih J.-Y.;Ho C.-C.;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Kuo S.-H.;Chia-Hsien Cheng;Yang P.-C.;Hsu F.-M.; Yang W.-C.; Xiao F.; Shih J.-Y.; Ho C.-C.; Chen Y.-F.; Tseng H.-M.; Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; CHIA-HSIEN CHENG; Yang P.-C.; Hsu F.-M. |
| 臺大學術典藏 |
2020-04-27T08:45:04Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; Yang J.C.H.; Wang J.; Babu K.G.; Douillard J.-Y.; Yoshino T.; Peters S.; Ahn H.K.; Kim T.-Y.; Ahn Y.C.; Senan S.; CHIA-HSIEN CHENG; Chua K.L.M.; Alip A.; Nakayama Y.; Park K.;Vansteenkiste J.;Lee K.H.;Pentheroudakis G.;Zhou C.;Prabhash K.;Seto T.;Voon P.J.;Tan D.S.W.;Yang J.C.H.;Wang J.;Babu K.G.;Nakayama Y.;Alip A.;Chua K.L.M.;Chia-Hsien Cheng;Senan S.;Ahn Y.C.;Kim T.-Y.;Ahn H.K.;Peters S.;Yoshino T.;Douillard J.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Chiun Hsu; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:09Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.;Chen I.-C.;Chiun Hsu;Chang S.-Y.;Chien S.-F.;Chen Y.-C.;Hu F.-C.;Yang J.C.-H.;Cheng A.-L.;Yeh K.-H.; Kao H.-F.; Chen I.-C.; Chiun Hsu; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:05Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Shao Y.-Y.;Chiun Hsu;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Chiun Hsu; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:11Z |
Survival of patients with small cell lung carcinoma in Taiwan
|
Kuo Y.-H.; Lin Z.-Z.; Yang Y.-Y.; YU-YUN SHAO; Shau W.-Y.; Kuo R.N.C.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study
|
Lin Z.-Z.; Shau W.-Y.; YU-YUN SHAO; Yang Y.-Y.; Kuo R.N.-C.; Yang J.C.-H.; Laie M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
|
YU-YUN SHAO; Shau W.-Y.; Lin Z.-Z.; Chen H.-M.; Kuo R.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:08Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Hsu C.; YU-YUN SHAO; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:04Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
Liao B.-C.;Yu-Yun Shao;Chen H.-M.;Shau W.-Y.;Lin Z.-Z.;Kuo R.N.;Lai C.-L.;Chen K.-H.;Cheng A.-L.;Yang J.C.-H.;Lai M.-S.; Liao B.-C.; YU-YUN SHAO; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Yu-Yun Shao;Hsu C.;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice
|
Liang Y.-H.; YU-YUN SHAO; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-03-30T08:50:53Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y. |
